Multiple I-SPY investigators scheduled to present

Presentation of advances from the groundbreaking I-SPY 2 TRIAL

I-SPY investigators lauded for ‘mammoth task’ of imaging quality control in multicenter trials

A combination of poly (ADP-ribose) polymerase (PARP) enzyme inhibitor olaparib and anti-PD-L1 monoclonal antibody immunotherapy agent durvalumab, both from AstraZeneca, will be evaluated in I-SPY 2.

Three results from I-SPY’s adaptive trial design being showcased at ASCO 2018.

OncLive® announced Dr. Laura Esserman as an inductee of the 2018 Giants of Cancer Care® recognition program.

Data Presented at San Antonio Breast Cancer Symposium Show Significant and Clinically Impactful Relationship Between pCR and Event-Free Survival in High-Risk Breast Cancer.

New Data Analyses Presented at San Antonio Breast Cancer Symposium Spotlight Predictive Response to Pembrolizumab and MK-2206, and Demonstrate Improved Predictive Performance of Breast MRI

With this new technology, the I-SPY 2 TRIAL can better help match agents, combinations, and additional targeted interventions to women with high-risk breast cancers.

Data to Be Presented at 2017 ASCO Annual Meeting Include Findings in Patients with Locally Advanced Triple-Negative (TNBC) and Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Breast Cancers

In conjunction with Triple Negative Breast Cancer Day, HemOnc Today presents five updates in the treatment of triple-negative breast cancer and on associated disparities that may impact your practice.

The triple-negative breast cancer (TNBC) pipeline is transforming, experts say, with the potential additions of immunotherapy and PARP inhibitors.